GlassScriptPhysician profile
Reda S Bestawrous
NPI 1811995723
$1,853.23
in general payments reported to CMS, 2019-2025
31 companies · $734 in 2025
The $734 reported for 2025 was more than what 80% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $152 · 2020: $97.94 · 2021: $304 · 2022: $119 · 2023: $203 · 2024: $242 · 2025: $734.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,180.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,179.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $294.44 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $219.98 | 2020-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $153.46 | 2021 | |
| Abbott Laboratories | $150.39 | 2019-2025 | Freestyle Libre 3, Assurity |
| Dexcom, INC. | $139.05 | 2025 | Dexcom Stelo Glucose Biosensor, Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Glaxosmithkline, LLC. | $119.78 | 2020-2023 | Trelegy Ellipta, Shingrix, Arexvy |
| Amgen INC. | $98.49 | 2024-2025 | Repatha, Repatha, Prolia |
| Shield Therapeutics INC | $79.22 | 2024 | |
| Merck Sharp & Dohme LLC | $60.23 | 2019-2021 | |
| Exact Sciences Corporation | $55.20 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $45.68 | 2024 | Trulance, Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.06 | 2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $31.17 | 2021 | |
| Lilly USA, LLC | $31.17 | 2019-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $29.88 | 2022-2023 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Corcept Therapeutics | $26.96 | 2025 | Korlym |
| Amarin Pharma, INC. | $25.96 | 2019-2021 | |
| Allergan, INC. | $25.32 | 2019-2020 | |
| Inspire Medical Systems, INC. | $25.06 | 2023 | Inspire |
| Phadia US INC. | $21.11 | 2022 | |
| Xeris Pharmaceuticals, INC. | $20.70 | 2025 | Gvoke Hypopen |
| Novartis Pharmaceuticals Corporation | $18.62 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $18.31 | 2022 | |
| Phathom Pharmaceuticals, INC. | $18.13 | 2025 | Voquezna |
| Azurity Pharmaceuticals, INC. | $17.45 | 2025 | Azmiro |
| Pfizer INC. | $16.68 | 2022 | |
| Seqirus USA INC | $16.08 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $15.01 | 2021 | |
| Globus Medical, INC. | $14.89 | 2025 | Senza |
| Lucid Diagnostics INC. | $14.77 | 2023 | |
| Antares Pharma, INC. | $13.98 | 2024 | Xyosted |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Reda Bestawrous listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.